Home
Clinical Trials
Use Of GW274150 In The Prophy...

Use Of GW274150 In The Prophylactic Treatment Of Migraine

Last Updated: 2016-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

430 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the prevention of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the prophylactic treatment of migraine headache.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

NCT00319137

Migraine Disorders Migraine

COMPLETED PHASE2

A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention

NCT01617941

Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening

WITHDRAWN PHASE2

The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache

NCT02485340

Migraine

COMPLETED NA

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

NCT01513291

Migraine Headache

COMPLETED PHASE2

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

NCT02021474

Migraine Prophylaxis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

GW274150 - 5mg or 30mg

Group Type EXPERIMENTAL

GW274150

Intervention Type DRUG

The tablets used in this study will contain either 5mg or 30mg of GW274150

Placebo

Intervention Type OTHER

Placebo to Match GW274150

Arm 2

Placebo to match GW274150

Group Type PLACEBO_COMPARATOR

GW274150

Intervention Type DRUG

The tablets used in this study will contain either 5mg or 30mg of GW274150

Placebo

Intervention Type OTHER

Placebo to Match GW274150

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW274150

The tablets used in this study will contain either 5mg or 30mg of GW274150

Intervention Type DRUG

Placebo

Placebo to Match GW274150

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Suffering from migraine with or without aura.
* Migraine for at least one year, and the age of onset was prior to 50 years.
* Consistent migraine headache over time and has had at least 3 migraine headache attacks but less than 15 days with headache (migraine or non-migraine) per month in each of the three months prior to the Screening Visit and maintains this requirement during the baseline period.
* Able to distinguish migraine headache attacks as discreet attacks from other headaches (i.e. tension-type headaches).
* No clinically significant abnormality identified on the medical or laboratory evaluation. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the doctor considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
* Written informed consent prior to entry into the study.
* Females who are: a) non-childbearing potential or, b) of child-bearing potential, has a negative pregnancy test at screen, and is taken adequate contraceptive measures.

Exclusion Criteria

* As a result of the medical interview, physical examination or screening investigations, that the doctor considers the subject unfit for the study.
* Headache for 15 days per month or greater in any of the three months (90 days) preceding the Screening Visit.
* History of alcohol, substance or drug abuse within the last year.
* Taken a migraine prophylactic medication within 1 month of the Screening Visit.
* Uses an opiate as first line acute treatment for migraine attacks.
* History of ergotamine, triptan, opioid, or combination medication intake on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months.
* History of simple analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months.
* Failed two or more adequate treatments of migraine prophylaxis, where failure is defined as a lack of efficacy with a treatment duration of at least 8 weeks or withdrawal of treatment due to treatment intolerance.
* Uncontrolled hypertension at the Screening Visit, defined as systolic blood pressure \>140mmHg or diastolic blood pressure \>90mmHg.
* Taking cyclosporine and/or aminoglycosides.
* Evidence of renal impairment - calculated creatinine clearance \<60ml/min or clinically relevant finding on urinalysis.
* History of drug or other allergy which, in the opinion of the doctor, makes the subject unsuitable for participation in the study.
* Concurrently participating in another clinical study or investigational drug trial or has participated within the previous 3 months or is planning to participate in another drug or device study at any time during this study (screening through follow-up) or has had previous exposure to GW274150 in Part 1 of the study.
* Felt to be at risk of non-compliance (for taking study medication or for completing the electronic diary (e-diary)), in the doctor's opinion.
* Pregnant or nursing women.
* History of, or risk factors for, HIV, Hepatitis B and Hepatitis C.
* Past or present disease, which as judged by the doctor, may affect the outcome of this study. These diseases include, but are not limited to history of liver or renal disease in the 6 months prior to screening.
* Clinically significant abnormalities in safety laboratory analysis at the Screening Visit, particularly any abnormal liver or pancreatic function test at the Screening Visit.
* Not covered by social security.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers